Cargando…

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

Emerging data suggest that locoregional cancer therapeutic approaches with oncolytic viruses can lead to systemic anti-tumour immunity, although the appropriate targets for intratumoral immunomodulation using this strategy are not known. Here we find that intratumoral therapy with Newcastle disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zamarin, Dmitriy, Holmgaard, Rikke B., Ricca, Jacob, Plitt, Tamar, Palese, Peter, Sharma, Padmanee, Merghoub, Taha, Wolchok, Jedd D., Allison, James P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316835/ https://www.ncbi.nlm.nih.gov/pubmed/28194010 http://dx.doi.org/10.1038/ncomms14340

Ejemplares similares

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection
por: Zamarin, Dmitriy, et al.
Publicado: (2013)

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
por: Holmgaard, Rikke B., et al.
Publicado: (2016)

Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model
por: Holmgaard, Rikke B, et al.
Publicado: (2014)

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
por: Ricca, Jacob M., et al.
Publicado: (2018)

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
por: Oseledchyk, Anton, et al.
Publicado: (2018)

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B., et al.
Publicado: (2013)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B, et al.
Publicado: (2013)

Immunotherapy and the belly of the beast
por: Merghoub, Taha, et al.
Publicado: (2014)

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
por: Khalil, Danny, et al.
Publicado: (2015)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Wang, Weiyi, et al.
Publicado: (2021)

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013)

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
por: Jelinic, Petar, et al.
Publicado: (2018)

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
por: Fan, Xiaozhou, et al.
Publicado: (2014)

Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2013)

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient
por: Jiménez-Sánchez, Alejandro, et al.
Publicado: (2017)

Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment
por: Zappasodi, Roberta, et al.
Publicado: (2014)

Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2014)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
por: Yang, Ning, et al.
Publicado: (2022)

APR-246 increases tumor antigenicity independent of p53
por: Michels, Judith, et al.
Publicado: (2023)

The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor protein
por: Ramos-Espiritu, Lavoisier, et al.
Publicado: (2016)

An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity
por: Maus, Marcela V, et al.
Publicado: (2017)

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
por: Campesato, Luis Felipe, et al.
Publicado: (2020)

ICO investors
por: Fahlenbrach, Rüdiger, et al.
Publicado: (2020)

Discovery of Intratumoral Oncolytic Bacteria Toward Targeted Anticancer Theranostics
por: Goto, Yamato, et al.
Publicado: (2023)

Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment
por: Khushalani, Nikhil I., et al.
Publicado: (2023)

Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity
por: Avogadri, Francesca, et al.
Publicado: (2010)

Oncolytic vaccinia virus induces a novel phenotype of CD8(+) effector T cells characterized by high ICOS expression
por: Yamashita, Midori, et al.
Publicado: (2021)

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
por: Yin, Jie, et al.
Publicado: (2017)

Colloque ICO '89
por: Moulin, B, et al.
Publicado: (1989)

The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy
por: Solinas, Cinzia, et al.
Publicado: (2020)

Role of endocytosis and trans‐endocytosis in ICOS costimulator‐induced downmodulation of the ICOS Ligand
por: Aragoneses‐Fenoll, Laura, et al.
Publicado: (2021)

Influenza Virus PB1-F2 Protein Induces Cell Death through Mitochondrial ANT3 and VDAC1
por: Zamarin, Dmitriy, et al.
Publicado: (2005)

OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs
por: Yang, Ning, et al.
Publicado: (2023)

A Single Mutation in the PB1-F2 of H5N1 (HK/97) and 1918 Influenza A Viruses Contributes to Increased Virulence
por: Conenello, Gina M, et al.
Publicado: (2007)

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
por: Hirschhorn-Cymerman, Daniel, et al.
Publicado: (2009)

Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism
por: He, Changhao, et al.
Publicado: (2022)

ICOS-deficient and ICOS YF mutant mice fail to control Toxoplasma gondii infection of the brain
por: O’Brien, Carleigh A., et al.
Publicado: (2020)

T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks
por: Tkach, Karen E, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_g15kaalog45cl4amofplg5844c